Heron Therapeutics Inc (NAS:HRTX)
$ 3.6 -0.035 (-0.96%) Market Cap: 542.35 Mil Enterprise Value: 650.00 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 63/100

Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 03:00PM GMT
Release Date Price: $5.83
Serge Belanger
Needham & Company, LLC - Analyst

Hi, good morning. Welcome to the 21st Annual Needham Healthcare Conference. I'm Serge Belanger, one of the healthcare analysts at Needham. And we're happy to have for our next session, Heron Therapeutics. We have Barry Quart, the company's CEO; as well as John Poyhonen, the company's Chief Commercial Officer. So, gentlemen, I'll hand it off to you guys. Do you want to start providing I guess an overview of the company and where you are in the launch of ZYNRELEF?

Barry Quart
Heron Therapeutics, Inc. - CEO & Chairman

Yeah, definitely happy to do that. Thanks, Serge. I appreciate the opportunity to be here. And so for those that are not familiar with Heron, we have three commercial products. Two of them are in the CINV space, chemotherapy-induced nausea and vomiting, and that we have two products of different mechanisms that are used together potentially or separately, CINVANTI and SUSTOL. And John will be able to give an update in terms of the commercial success of these products, but we have been

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot